California-based AI biotechnology company Creyon Bio has emerged from stealth with USD 40 million in seed and Series A financing co-led by DCVC Bio and Lux Capital. Other investors including Casdin Capital and BioBrit also participated in the round.
The proceeds will be directed toward accelerating the development of its AI-powered computational platform, growing its team, and establishing an internal pipeline.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.